A phase 1, first-in-human (FIH) study evaluating the safety, pharmacokinetics, and efficacy of ABBV-969 in patients with metastatic castration-resistant prostate cancer (mCRPC).
Year: 2026
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Tanya B. Dorff, Avivit Peer, Manish R. Sharma, Anthony M. Joshua, John D. Powderly, Yutaka Shimazu, Rahul Raj Aggarwal, Benedito A. Carneiro, Russell Zelig Szmulewitz, Linu Abraham, Sumiko Okubo, Claudina Stevenson, Samaneh Alaei, Song Wang, Muhammad Jalaluddin, Oluwadamilola Ogunyankin, Sarah Mudd, David I. Quinn, Fred Saad, Anthony W. Tolcher
Institutions: City Of Hope National Medical Center, Rambam Health Care Campus, St Vincent's Hospital Sydney, The Kinghorn Cancer Centre, Carolina BioOncology Institute, Kyoto University, University of California, San Francisco, Brown University, University of Chicago, AbbVie (United States), Centre Hospitalier de l’Université de Montréal, Université de Montréal
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
Funder: AbbVie
OpenAlex ID: W7162521111